The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.

What Was Tested

The paper reports a study of Atenolol, published as a randomized controlled trial.

The aim of this study was to investigate the effect of the plasma concentration of irbesartan, a specific angiotensin II type 1 receptor (AT1R) antagonist, and the blood pressure response in relation to AT1R gene polymorphisms.

Who Took Part

The study group was 42 patients.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Plasma irbesartan was analyzed in 42 patients with mild-to-moderate hypertension and left ventricular hypertrophy from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Atenolol study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Atenolol, so expectations could not easily colour the readings.

Five AT1R gene polymorphisms were analyzed by minisequencing.

What Was Measured

PubMed files the paper under topics including Adrenergic beta-Antagonists, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Atenolol, Biphenyl Compounds, Blood Pressure and Genotype.

What This Means in Plain Language

The paper is a randomized and double-blind study of Atenolol in 42 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (American journal of hypertension), a journal based in United States.

More context: all human trials.